Technical Analysis for OCUP - Ocuphire Pharma, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Historical OCUP trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Doji - Bearish? | Reversal | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Wide Bands | Range Expansion | 2.30% | |
MACD Bearish Signal Line Cross | Bearish | 8.04% | |
20 DMA Support | Bullish | 8.04% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | 8.04% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 8.04% | |
NR7 | Range Contraction | 8.04% | |
Wide Bands | Range Expansion | 8.04% | |
Down 3 Days in a Row | Weakness | 8.04% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
10 DMA Support | 2 days ago | |
Rose Above 10 DMA | 2 days ago | |
60 Minute Opening Range Breakdown | 2 days ago | |
Down 3% | 2 days ago | |
Down 2 % | 2 days ago |
Get this analysis on your stocks daily!
- Earnings date: 09/27/2019
Ocuphire Pharma, Inc. Description
Ocuphire is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances, pharmacologically-induced mydriasis, and presbyopia. Ocuphire’s second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation, and commercialization of drugs in key global markets.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Eye Organ Systems Diabetes Inflammation Ophthalmic Ophthalmology Vascular Diseases Retina Diabetic Retinopathy Macular Edema Blindness Vision Diabetic Macular Edema Retinopathy Night Vision Molecule Product Angiogenesis Presbyopia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 7.65 |
52 Week Low | 1.2626 |
Average Volume | 72,619 |
200-Day Moving Average | 3.21 |
50-Day Moving Average | 5.84 |
20-Day Moving Average | 6.49 |
10-Day Moving Average | 7.06 |
Average True Range | 0.56 |
ADX | 33.43 |
+DI | 24.33 |
-DI | 14.59 |
Chandelier Exit (Long, 3 ATRs ) | 5.97 |
Chandelier Exit (Short, 3 ATRs ) | 6.96 |
Upper Bollinger Band | 7.78 |
Lower Bollinger Band | 5.21 |
Percent B (%b) | 0.74 |
BandWidth | 39.60 |
MACD Line | 0.35 |
MACD Signal Line | 0.38 |
MACD Histogram | -0.0238 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 8.01 | ||||
Resistance 3 (R3) | 7.94 | 7.57 | 7.86 | ||
Resistance 2 (R2) | 7.57 | 7.35 | 7.61 | 7.81 | |
Resistance 1 (R1) | 7.35 | 7.21 | 7.17 | 7.42 | 7.76 |
Pivot Point | 6.98 | 6.98 | 6.89 | 7.02 | 6.98 |
Support 1 (S1) | 6.76 | 6.76 | 6.58 | 6.83 | 6.48 |
Support 2 (S2) | 6.39 | 6.62 | 6.43 | 6.43 | |
Support 3 (S3) | 6.17 | 6.39 | 6.38 | ||
Support 4 (S4) | 6.24 |